

DAFTAR PUSTAKA

- Abdulkareem, I.H., 2013. Aetio-pathogenesis of breast cancer. *Niger. Med. J.* 54, 371–5.
- Ali, S., Coombes, R.C., 2002. Endocrine-Responsive Breast Cancer and Strategies for Combating Resistance. *Nat. Rev. Cancer* 2, 101–112.
- Aryandono, T., Harijadi, Soeripto, 2006a. Hormone receptor status of operable breast cancers in Indonesia: correlation with other prognostic factors and survival. *Asian Pac. J. Cancer Prev.* 7, 321–324.
- Aryandono, T., Harijadi, Soeripto, 2006b. Survival from operable breast cancer: prognostic factors in Yogyakarta, Indonesia. *Asian Pac. J. Cancer Prev.* 7, 455–9.
- Aryandono, T., Harijadi, Soeripto, 2006c. Breast cancer in young women: prognostic factors and clinicopathological features. *Asian Pac. J. Cancer Prev.* 7, 451–454.
- Azim, H.A., Nguyen, B., Brohée, S., Zoppoli, G., Sotiriou, C., 2015. Genomic aberrations in young and elderly breast cancer patients. *BMC Med.* 13, 266.
- Azim, H. a, Partridge, A.H., Azim Jr., H.A., Partridge, A.H., 2014. Biology of breast cancer in young women. *Breast Cancer Res.* 16, 427.
- Azim, H., Azim Jr., H.A., 2013. Targeting RANKL in breast cancer: bone metastasis and beyond. *Expert Rev Anticancer Ther* 13, 195–201.
- Barzanti, F., Dal Susino, M., Volpi, A., Amadori, D., Riccobon, A., Scarpi, E., Medri, L., Bernardi, L., Naldi, S., Aldi, M., Gaudio, M., Zoli, W., 2000. Comparison between different cell kinetic variables in human breast cancer. *Cell Prolif* 33, 75–89.
- Behjatnia, B., Sim, J., Bassett, L., Moatamed, N., Apple, S., 2010. Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. *Int. J. Clin. Pathol.* 3, 458–460.
- Bhoo-pathy, N., Yip, C., Hartman, M., Gils, C.H. Van, Verkooijen, H.M., 2013. Breast cancer research in Asia : Adopt or adapt Western knowledge ? *Eur. J. Cancer* 49, 703–709.
- Canello, G., Maisonneuve, P., Rotmensz, N., Viale, G., Mastropasqua, M.G., Pruneri, G., Montagna, E., Iorfida, M., Mazza, M., Balduzzi, A., Veronesi, P., Luini, A., Intra, M., Goldhirsch, A., Colleoni, M., 2013. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. *Ann. Oncol.* 24, 661–668.
- Carey, L.A., 2010. Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. *Clin. Breast Cancer* 10, 188–95.
- Carroll, J.S., Brown, M., 2006. Estrogen receptor target gene: an evolving concept. *Mol. Endocrinol.* 20, 1707–1714.
- Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T.R., Fox, E.A., Silver, P.A., Brown, M., 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* 122, 33–43.
- Cheang, M.C.U., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P.S., Parker, J.S., Perou, C.M., Ellis, M.J., Nielsen,

- T.O., 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J. Natl. Cancer Inst.* 101, 736–750.
- Chu P G ; Weiss L M, 2002. Keratin expression in human tissues and neoplasms. *Histopathology* 43, 403–439.
- Chuthapisith, S., Permsapaya, W., Warnnissorn, M., Akewanlop, C., Sirivatanauksorn, V., Prasarttong, P., 2012. Breast Cancer Subtypes Identified by the ER , PR and HER-2 Status in Thai Women. *Asian Pacific J. Cancer Prev.* 13, 459–462.
- Clarke, C.A., Keegan, T.H.M., Yang, J., Press, D.J., Kurian, A.W., Patel, A.H., Lacey, J. V, 2012. Age-Specific Incidence of Breast Cancer Subtypes : Understanding the Black – White Crossover. *J. Natl. Cancer Inst.* 104.
- Creighton, C.J., 2012. The molecular profile of luminal B breast cancer. *Biol. Targets Ther.* 6, 289–297.
- de Kruijf, E.M., Bastiaannet, E., Rubertá, F., de Craen, A.J.M., Kuppen, P.J.K., Smit, V.T.H.B.M., van de Velde, C.J.H., Liefers, G.J., 2014. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. *Mol. Oncol.* 8, 1014–1025.
- Dedić Plavetić, N., Kulić, A., Vrbaneć, D., 2012. Role of HER2 signaling pathway in breast cancer: Biology, detection and therapeutical implications. *Period. Biol.* 114, 505–510.
- Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P., Narod, S.A., 2007. Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin. Cancer Res.* 13, 4429–4434.
- Devi, C.R.B., Tang, T.S., Corbex, M., 2012. Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups : Chinese , Malay and natives of Sarawak , *Malaysia. Int. J. Cancer* 0, 1–9.
- Elidrissi Errahhali, M., Elidrissi Errahhali, M., Ouarzane, M., El Harroudi, T., Afqir, S., Bellaoui, M., 2017. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. *BMC Womens. Health* 17, 1-11.
- Elkablawy, M.A., Albasri, A.M., Hussainy, A.S., Nouh, M.M., Alhujaily, A., 2015. Molecular profiling of breast carcinoma in Almadinah, KSA: Immunophenotyping and clinicopathological correlation. *Asian Pacific J. Cancer Prev.* 16, 7819–7824.
- Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., Lluch, A., 2012. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. *Cancer Treat. Rev.* 38, 698–707.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136, E359–E386.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F., 2013. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [internet]. URL http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (diakses

tanggal 25 Maret 2017).

- Firdaus, V., Asri, A., Khambri, D., 2016. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *J. Kesehatan*. 5, 165–172.
- Foulkes, W.D., Reis-Filho, J.S., Narod, S. a., 2010. Tumor size and survival in breast cancer--a reappraisal. *Nat. Rev. Clin. Oncol.* 7, 348–53.
- Gnant, M., Harbeck, N., Thomssen, C., 2011. St. Gallen 2011: Summary of the consensus discussion. *Breast Care* 6, 136–141.
- Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thrlimann, B., Senn, H.J., Albain, K.S., Ander, F., Bergh, J., Bonnefoi, H., Bretel-Morales, D., Burstein, H., Cardoso, F., Castiglione-Gertsch, M., Coates, A.S., Colleoni, M., Costa, A., Curigliano, G., Davidson, N.E., Leo, A. Di, Ejlersen, B., Forbes, J.F., Gelber, R.D., Gnant, M., Goldhirsch, A., Goodwin, P., Goss, P.E., Harris, J.R., Hayes, D.F., Hudis, C.A., Ingle, J.N., Jassem, J., Jiang, Z., Karlsson, P., Loibl, S., Morrow, M., Namer, M., Osborne, C.K., Partridge, A.H., Penault-Llorca, F., Perou, C.M., Piccart-Gebhart, M.J., Pritchard, K.I., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z.M., Smith, I., Thrlimann, B., Toi, M., Tutt, A., Untch, M., Viale, G., Watanabe, T., Wilcken, N., Winer, E.P., Wood, W.C., 2013. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. *Ann. Oncol.* 24, 2206–2223.
- Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thrlimann, B., Senn, H.J., 2011. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. *Ann. Oncol.* 22, 1736–1747.
- Guo, L., Hou, X., Dilimina, Y., Wang, B., 2014. Expression of ER, PR and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer. *Exp. Ther. Med.* 7, 1077–1082.
- Gusterson, B., 2009. Do “basal-like” breast cancers really exist? *Nat. Rev. Cancer* 9, 128–134.
- Hammond, M.E.H., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., Mcshane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C.G., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L., Wolff, A.C., 2010. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch. Pathol. Lab. Med.* 134.
- Hashmi, A.A., Edhi, M.M., Naqvi, H., Khurshid, A., Faridi, N., 2014. Molecular subtypes of breast cancer in south Asian population by immunohistochemical profile and her2neu gene amplification by fish technique: Association with other clinicopathologic parameters. *Breast J.* 20, 578–585.

- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., Backlund, M.G., Yin, Y., Khramtsov, A.I., Bastein, R., Quackenbush, J., Glazer, R.I., Brown, P.H., Green, J.E., Kopelovich, L., Furth, P.A., Palazzo, J.P., Olopade, O.I., Bernard, P.S., Churchill, G.A., Van Dyke, T., Perou, C.M., 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol.* 8, R76.
- Holm, J., Eriksson, L., Ploner, A., Eriksson, M., Rantalainen, M., Li, J., Hall, P., Czene, K., Institutet, K., Institutet, K., 2017. Assessment of breast cancer risk factors reveals subtype heterogeneity. *Cancer Res.* 1-14
- Hynes, N.E., Lane, H.A., 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat. Rev. Cancer* 5, 341–54.
- Inwald, E.C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., Ortmann, O., 2013. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. *Breast Cancer Res. Treat.* 139, 539–552.
- Irwan, Azamris, Bachtiar, H., 2015. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara Antara Pasien Kanker Payudara. *MKA* 38, 208–217.
- Jenkins, E.O., Deal, A.M., Anders, C.K., Prat, A., Perou, C.M., Carey, L.A., Muss, H.B., 2014. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. *Oncologist* 19, 1076–83.
- Jia, W.-J., Jia, H.-X., Feng, H.-Y., Yang, Y.-P., Chen, K., Su, F.-X., 2014. HER2-enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy. *Asian Pac. J. Cancer Prev.* 15, 315–320.
- Judistira, J., 2012. Hubungan Antara Subtipe Imunohistokimia Karsinoma Payudara dengan Karakteristik Klinikopatologisnya di RSUP DR. Sardjito Yogyakarta tahun 2010-2011. *Tesis*. Universitas Gadjah Mada. Yogyakarta
- Kementrian Kesehatan RI, 2015. Stop Kanker. Infodatin. hal 1-6. [internet] <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>. Diakses tanggal 12 Desember 2016.
- Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C.U., Voduc, D., Speers, C.H., Nielsen, T.O., Gelmon, K., 2010. Metastatic behavior of breast cancer subtypes. *J. Clin. Oncol.* 28, 3271–3277.
- Kolečkova, M., Kolař, Z., Ehrmann, J., Kořínková, G., Trojanec, R., 2017. Age-associated prognostic and predictive biomarkers in patients with breast cancer. *Oncol. Lett.* 4201–4207.
- Kumar, V., Abbas, A., Aster, J., 2015. Robbins and Contrans Pathologic Basis of Disease, 9 th edition. ed. Elsevier Inc.
- Lambertini, M., Santoro, L., Del Mastro, L., Nguyen, B., Livraghi, L., Ugolini, D., Peccatori, F.A., Azim, H.A., 2016. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. *Cancer Treat. Rev.* 49, 65–76.
- Lee, Y., Kang, E., Lee, A.S., Baek, H., Kim, E.K., Park, S.Y., Kim, J.H., Kim, Y.J., Kim, S.H., Kim, I.A., Eom, K.Y., Kim, S.W., 2015. Outcomes and

- recurrence patterns according to breast cancer subtypes in Korean women. *Breast Cancer Res. Treat.* 151, 183–190.
- Lehmann, B.D.B., Bauer, J. a J., Chen, X., Sanders, M.E., Chakravarthy, a B., Shyr, Y., Pietenpol, J. a, 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J. Clin. Invest.* 121, 2750–2767.
- Li, H., Sun, X., Miller, E., Wang, Q., Tao, P., Liu, L., Zhao, Y., Wang, M., Qi, Y., Li, J., 2017. BMI , reproductive factors , and breast cancer molecular subtypes : A case-control study and meta-analysis. *J. Epidemiol.* 27, 143–151.
- Liedtke, C., Rody, A., Gluz, O., Baumann, K., Beyer, D., Kohls, E.-B., Lausen, K., Hanker, L., Holtrich, U., Becker, S., Karn, T., 2015. The prognostic impact of age in different molecular subtypes of breast cancer. *Breast Cancer Res. Treat.* 152, 667–673.
- Liu, Y.-H., Wang, O.-C., Chen, E.-D., Cai, Y.-F., Pan, C.-M., Yang, F., Zhang, X.-H., 2015. Unexpected features of breast cancer subtype. *World J. Surg. Oncol.* 13, 249.
- Liu, Y., Xin, T., Huang, Q.J.D., 2013. CD147 , MMP9 expression and clinical significance of basal-like breast cancer. *Med Oncol* 30, 1–5.
- Livasy, C.A., Karaca, G., Nanda, R., Tretiakova, M.S., Olopade, O.I., Moore, D.T., Perou, C.M., 2006. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod. Pathol.* 19, 264–271.
- Ly, M., Karim, A., Levy, P., Ali, B., Badiaga, Y., 2012. Reducing the Worldwide Burden of Cancer High Incidence of Triple-Negative Tumors in Sub-Saharan Africa : A Prospective Study of Breast Cancer Characteristics and Risk Factors in Malian Women Seen in a Bamako University Hospital. *Oncology* 83, 257–263.
- Maiti, B., Kundranda, M.N., Spiro, T.P., Daw, H.A., 2010. The association of metabolic syndrome with triple-negative breast cancer. *Breast Cancer Res. Treat.* 121, 479–483.
- McAdam, A.J., Milner, D.A., Sharpe, A.H., 2015. Infectious Diseases, Ninth Edit. ed, Robbins and Cotran Pathologic Basis of Disease. Elsevier Inc., Canada.
- Medina, V.M., Laudico, a, Mirasol-Lumague, M.R., Brenner, H., Redaniel, M.T., 2010. Cumulative incidence trends of selected cancer sites in a Philippine population from 1983 to 2002: a joinpoint analysis. *Br. J. Cancer* 102, 1411–4.
- Moatamed, N.A., Apple, S.K., 2006. Extensive sampling changes T-staging of infiltrating lobular carcinoma of breast: A comparative study of gross versus microscopic tumor sizes. *Breast J.* 12, 511–517.
- Morrison, D.H., Rahardja, D., King, E., Peng, Y., Sarode, V.R., 2012. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. *Br. J. Cancer* 107, 382–387.
- Munirah, M.A., Siti-Aishah, M.A., Reena, M.Z., Sharifah, N.A., Rohaizak, M., Norlia, A., Rafie, M.K.M., Asmiati, A., Hisham, A., Fuad, I., Shahrin, N.S., Das, S., 2011. Identification of different subtypes of breast cancer using tissue microarray. *Rom. J. Morphol. Embryol.* 52, 669–677.

- Munjal, K., Ambaye, A., Evans, M.F., Mitchell, J., Nandedkar, S., Cooper, K., 2009. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in indian patients. *Asian Pacific J. Cancer Prev.* 10, 773–778.
- Naidoo, K., Pinder, S.E., 2016. Immunohistochemistry for Triple-Negative Breast Cancer. In: *Breast Cancer: Methods and Protocols, Methods in Molecular Biology*. vol. 1406. Springer. pp. 39–50.
- Narod, S.A., 2012. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. *Curr. Oncol.* 19, 249–253.
- Ng, C.H., Bhoo Pathy, N., Taib, N.A., Teh, Y.C., Mun, K.S., Amiruddin, A., Sinuraya, E.S., Rhodes, A., Yip, C.H., 2011. Comparison of breast cancer in Indonesia and Malaysia - A clinico-pathological study between dharmais cancer centre Jakarta and university Malaya medical centre, Kuala Lumpur. *Asian Pacific J. Cancer Prev.* 12, 2943–2946.
- Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L. a, Ragaz, J., Gown, A.M., Gilks, C.B., 2004. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. *Clin. Cancer Res.* 10, 5367–5374.
- Nishimura, R., Osako, T., Okumura, Y., Hayashi, M., Totoyozumi, Y., Arima, N., 2010. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. *Exp. Ther. Med.* 1, 747–754.
- Norsa'adah, B., Rampal, K.G., Rahmah, M.A., Naing, N.N., Biswal, B.M., 2011. Diagnosis delay of breast cancer and its associated factors in Malaysian women. *BMC Cancer* 11, 2-8.
- Onitilo, A.A., Engel, J.M., Greenlee, R.T., Mukesh, B.N., 2009. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. *Clin. Med. Res.* 7, 4–13.
- Park, S., Koo, J.S., Kim, M.S., Park, H.S., Lee, J.S., Lee, J.S., Kim, S. Il, Park, B.W., 2012. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *Breast* 21, 50–57.
- Perou, C.M., 2011. Molecular stratification of triple-negative breast cancers. *Oncologist* 16 Suppl 1, 61–70.
- Perou, C.M., Sørli, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C. a, Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L. a, Fluge, O., Pergamenschikov, a, Williams, C., Zhu, S.X., Lønning, P.E., Børresen-Dale, a L., Brown, P.O., Botstein, D., 2000. Molecular portraits of human breast tumours. *Nature* 406, 747–752.
- Pichard, C., Plu-Bureau, G., Neves-e Castro, M., Gompel, A., 2008. Insulin resistance, obesity and breast cancer risk. *Maturitas* 60, 19–30.
- Polyak, K., 2011. Review series introduction Heterogeneity in breast cancer 121.
- Porter, P., 2008. “Westernizing” Women’s Risks? Breast Cancer in Lower-Income Countries. *N. Engl. J. Med.* 358, 213–216.

- Radenkovic, S., Konjevic, G., Jurisic, V., Karadzic, K., Nikitovic, M., Gopcevic, K., 2013. Values of MMP-2 and MMP-9 in Tumor Tissue of Basal-Like Breast Cancer Patients. *Cell Biochem Biophys*. 1-10.
- Rakha, E.A., Elsheikh, S.E., Aleskandarany, M.A., Habashi, H.O., Green, A.R., Powe, D.G., El-Sayed, M.E., Benhasouna, A., Brunet, J.S., Akslen, L.A., Evans, A.J., Blamey, R., Reis-Filho, J.S., Foulkes, W.D., Ellis, I.O., 2009. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. *Clin. Cancer Res.* 15, 2302–2310.
- Reis-Filho, J.S., Weigelt, B., Fumagalli, D., Sotiriou, C., 2010. Molecular Profiling: Moving Away from Tumor Philately. *Sci. Transl. Med.* 2, 47ps43-47ps43.
- Rivenbark, A.G., O'Connor, S.M., Coleman, W.B., 2013. Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine. *Am. J. Pathol.* 183, 1113–1124.
- Runnak, M., Hazha, M. a, Hemin, H. a, Wasan, A. a, Rekawt, R.M., Michael, H.D., 2012. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. *BMC Womens. Health.* 12,1-10.
- Saadatmand, S., Bretveld, R., Siesling, S., Tilanus-Linthorst, M.M.A., 2015. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. *BMJ* 351, 1-4.
- Santosa, P., Ghozali, A., Irianiwati, 2015. Ekspresi c-kit dan beberapa faktor klinikopatologis karsinoma payudara subtype Basal-like. *Maj. Patol.* 24, 41–46.
- Schedin, P., Elias, A., 2004. Multistep tumorigenesis and the microenvironment. *Breast Cancer Res.* 6, 93–101.
- Shah, R., Rosso, K., Nathanson, S.D., 2014. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J. Clin. Oncol.* 5, 283-298.
- Shibuta, K., Ueo, H., Furusawa, H., Komaki, K., Rai, Y., Sagara, Y., Kamada, Y., Tamaki, N., 2011. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. *Breast Cancer* 18, 292–298.
- Sinn, H.P., Kreipe, H., 2013. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. *Breast Care* 8, 149–154.
- Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., Matese, J.C., Brown, P.O., Botstein, D., Eystein Lonning, P., Borresen-Dale, A.L., 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci.* 98, 10869–10874.
- Tamaki, M., Kamio, T., Kameoka, S., Kojimahara, N., Nishikawa, T., 2013. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. *World J Surg Oncol* 11, 1-13.
- Tang, P., Tse, G.M., 2016. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. *Arch. Pathol. Lab. Med.*

140, 806–814.

- Tang, P., Wang, J., Hicks, D.G., Wang, X., Schiffhauer, L., McMahon, L., Yang, Q., Shayne, M., Huston, A., Skinner, K. a, Griggs, J., Lyman, G., 2010. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. *Cancer Invest.* 28, 978–982.
- Tiwari, S., Malik, R., Rai, A., Balani, S., Jain, J., Pandey, D., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., Pradesh, M., 2015. Breast Cancer: Correlation of Molecular Classification with Clinicohistopathology. *Sch. J. Appl. Med. Sci.* 3, 1018–1026.
- Tran, B., Bedard, P.L., 2011. Luminal-B breast cancer and novel therapeutic targets. *Breast Cancer Res.* 13, 2-10.
- Turkoz, F.P., Solak, M., Petekkaya, I., Keskin, O., Kertmen, N., Sarici, F., Arik, Z., Babacan, T., Ozisik, Y., Altundag, K., 2013. Association between common risk factors and molecular subtypes in breast cancer patients. *The Breast* 22, 344–350.
- Visvader, J.E., 2009. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. *Genes Dev.* 23, 2563–2577.
- Wang, Y., Yin, Q., Yu, Q., Zhang, J., Liu, Z., Wang, S., Lv, S., Niu, Y., 2011. A retrospective study of breast cancer subtypes: The risk of relapse and the relations with treatments. *Breast Cancer Res. Treat.* 130, 489–498.
- Widodo, I., Dwianingsih, E.K., Triningsih, E., Utoro, T., Soeripto, 2014. Clinicopathological features of indonesian breast cancers with different molecular subtypes. *Asian Pac. J. Cancer Prev.* 15, 6109–13.
- Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., Oncology, A.S. of C., Pathologists, C. of A., 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. TL - 31. *J. Clin. Oncol.* 31, 3997–4013.
- Wong, F.Y., Chin, F.K., Lee, K.A., Soong, Y.L., Chua, E.T., 2011. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy. *Ann Acad Med Singapore* 40, 90–96.
- Yang, X.R., Sherman, M.E., Rimm, D.L., Lissowska, J., Brinton, L.A., Peplonska, B., Hewitt, S.M., Anderson, W.F., Szeszenia-Dabrowska, N., Bardin-Mikolajczak, A., Zatonski, W., Cartun, R., Mandich, D., Rymkiewicz, G., Ligaj, M., Lukaszek, S., Kordek, R., García-Closas, M., 2007. Differences in risk factors for breast cancer molecular subtypes in a population-based study. *Cancer Epidemiol. Biomarkers Prev.* 16, 439–443.
- Yersal, O., Barutca, S., 2014. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J. Clin. Oncol.* 5, 412–24.

- Youliden, D.R., Cramb, S.M., Yip, C.H., Baade, P.D., 2014. Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region. *Cancer Biol. Med.* 11, 101–15.
- Zaha, D.C., 2014. Significance of immunohistochemistry in breast cancer. *World J. Clin. Oncol.* 5, 382–92.
- Zaha, D.C., Lazar, E., Lazureanu, C., 2010. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. *Rom. J. Morphol. Embryol.* 51, 85–89.
- Zardavas, D., Irrthum, A., Swanton, C., Piccart, M., 2015. Clinical management of breast cancer heterogeneity. *Nat Rev Clin Oncol* 12, 381–394.